Lumosa Therapeutics Valuation
Is 6535 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 6535 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate 6535's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate 6535's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 6535?
Key metric: As 6535 barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.
| What is 6535's PB Ratio? | |
|---|---|
| PB Ratio | 50.4x |
| Book | NT$1.15b |
| Market Cap | NT$58.22b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 1525.7x |
| Enterprise Value/EBITDA | -169x |
| PEG Ratio | n/a |
Price to Book Ratio vs Peers
How does 6535's PB Ratio compare to its peers?
| Company | Forward PB | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 5x | ||
6472 Bora Pharmaceuticals | 6.9x | 22.7% | NT$81.0b |
4123 Center Laboratories | 1.9x | n/a | NT$36.2b |
1795 Lotus Pharmaceutical | 3.7x | 22.3% | NT$74.7b |
6919 Caliway Biopharmaceuticals | 7.7x | 182.1% | NT$75.0b |
6535 Lumosa Therapeutics | 50.4x | 20.2% | NT$58.2b |
Price-To-Book vs Peers: 6535 is expensive based on its Price-To-Book Ratio (50.4x) compared to the peer average (5x).
Price to Book Ratio vs Industry
How does 6535's PB Ratio compare vs other companies in the TW Pharmaceuticals Industry?
| 0 Companies | Price / Book | Estimated Growth | Market Cap |
|---|
| 0 Companies | Estimated Growth | Market Cap |
|---|
Price-To-Book vs Industry: 6535 is expensive based on its Price-To-Book Ratio (50.4x) compared to the TW Pharmaceuticals industry average (2.1x).
Price to Book Ratio vs Fair Ratio
What is 6535's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PB Ratio | 50.4x |
| Fair PB Ratio | n/a |
Price-To-Book vs Fair Ratio: Insufficient data to calculate 6535's Price-To-Book Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | NT$353.00 | NT$244.00 -30.9% | 4.7% | NT$254.00 | NT$228.00 | n/a | 3 |
| Nov ’25 | NT$361.50 | NT$244.00 -32.5% | 4.7% | NT$254.00 | NT$228.00 | n/a | 3 |
| Oct ’25 | NT$323.00 | NT$244.00 -24.5% | 4.7% | NT$254.00 | NT$228.00 | n/a | 3 |
| Sep ’25 | NT$260.50 | NT$244.00 -6.3% | 4.7% | NT$254.00 | NT$228.00 | n/a | 3 |
| Aug ’25 | NT$226.00 | NT$244.00 +8.0% | 4.7% | NT$254.00 | NT$228.00 | n/a | 3 |
| Jul ’25 | NT$240.00 | NT$244.00 +1.7% | 4.7% | NT$254.00 | NT$228.00 | n/a | 3 |
| Jun ’25 | NT$180.00 | NT$233.33 +29.6% | 5.2% | NT$250.00 | NT$222.00 | n/a | 3 |
Analyst Forecast: Target price is lower than the current share price.
Discover undervalued companies
YungShin Global Holding
NT$15.4b
Through its subsidiaries, invests in, manufactures, and sells medicines, animal drugs, agricultural chemicals, industrial medicines, and cosmetics in Taiwan, Mainland China, Japan, and the United States.
3705
NT$57.90
7D
8.2%
1Y
27.1%
Winston Medical Supply
NT$1.6b
Winston Medical Supply Co.,Ltd. develops, manufactures, and distributes pharmaceuticals, nutrition supplements, and cosmeceutical products.
6817
NT$88.30
7D
-1.6%
1Y
-13.4%
RBC Bioscience
NT$254.3m
Researches, develops, manufactures, and sells reagents and devices for life science and molecular diagnosis in Europe, the United States, Asia, Taiwan, Africa, and Australia.
6848
NT$19.60
7D
-0.5%
1Y
29.8%